Park JM - Search Results

1

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.

Park JM, Lake KD, Arenas JD, Fontana RJ. Park JM, et al. Liver Transpl. 2006 Jan;12(1):112-6. doi: 10.1002/lt.20562. Liver Transpl. 2006. PMID: 16382458 Free article.

2

Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing.

Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Hardinger KL, et al. Among authors: park jm. Am J Transplant. 2004 Apr;4(4):621-5. doi: 10.1111/j.1600-6143.2004.00383.x. Am J Transplant. 2004. PMID: 15023155 Free article.

3

Management of hypertension in solid-organ transplantation.

Park JM, Luan FL. Park JM, et al. Prog Transplant. 2005 Mar;15(1):17-22. doi: 10.1177/152692480501500103. Prog Transplant. 2005. PMID: 15839366 Review.

4

Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.

Luan FL, Chopra P, Park J, Norman S, Cibrik D, Ojo A. Luan FL, et al. Transplant Proc. 2006 Dec;38(10):3673-5. doi: 10.1016/j.transproceed.2006.10.105. Transplant Proc. 2006. PMID: 17175363

5

Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.

Gelone DK, Park JM, Lake KD. Gelone DK, et al. Among authors: park jm. Pharmacotherapy. 2007 Sep;27(9):1272-8. doi: 10.1592/phco.27.9.1272. Pharmacotherapy. 2007. PMID: 17723081 Free article. Clinical Trial.

6

Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.

Park JM, Lake KD, Cibrik DM. Park JM, et al. Ther Drug Monit. 2008 Oct;30(5):591-6. doi: 10.1097/FTD.0b013e3181858169. Ther Drug Monit. 2008. PMID: 18708992 Free PMC article.

7

Should heart, lung, and liver transplant recipients receive immunosuppression induction for kidney transplantation?

Ranney DN, Englesbe MJ, Muhammad W, Al-Holou SN, Park JM, Pelletier SJ, Punch JD, Lynch RJ. Ranney DN, et al. Among authors: park jm. Clin Transplant. 2010 Jan-Feb;24(1):67-72. doi: 10.1111/j.1399-0012.2009.00973.x. Epub 2009 Feb 17. Clin Transplant. 2010. PMID: 19222505 Free article.

8

Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.

Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Luan FL, et al. Among authors: park jm. J Am Soc Nephrol. 2009 Nov;20(11):2449-58. doi: 10.1681/ASN.2008111166. Epub 2009 Sep 17. J Am Soc Nephrol. 2009. PMID: 19762495 Free PMC article.

9

Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.

Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO. Luan FL, et al. Among authors: park jm. Transpl Infect Dis. 2010 Dec;12(6):473-9. doi: 10.1111/j.1399-3062.2010.00532.x. Transpl Infect Dis. 2010. PMID: 20576019 Free PMC article. Clinical Trial.

10

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

Yu MA, Park JM. Yu MA, et al. Among authors: park jm. Expert Opin Pharmacother. 2013 Apr;14(6):807-15. doi: 10.1517/14656566.2013.778244. Epub 2013 Mar 8. Expert Opin Pharmacother. 2013. PMID: 23469871 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,125 results

Search Page

Filters